Bennett JC
Hetrich MK
Garcia Quesada M
Sinkevitch JN
Deloria Knoll M
Feikin DR
Zeger SL
Kagucia EW
Cohen AL
Ampofo K
Brandileone MC
Bruden D
Camilli R
Castilla J
Chan G
Cook H
Cornick JE
Dagan R
Dalby T
Danis K
de Miguel S
De Wals P
Desmet S
Georgakopoulou T
Gilkison C
Grgic-Vitek M
Hammitt LL
Hilty M
Ho PL
Jayasinghe S
Kellner JD
Kleynhans J
Knol MJ
Kozakova J
Kristinsson KG
Ladhani SN
MacDonald L
Mackenzie GA
Mad'arova L
McGeer A
Mereckiene J
Morfeldt E
Mungun T
Munoz-Almagro C
Nuorti JP
Paragi M
Pilishvili T
Puentes R
Saha SK
Sahu Khan A
Savrasova L
Scott JA
Skoczynska A
Suga S
van der Linden M
Verani JR
von Gottberg A
Winje BA
Yildirim I
Zerouali K
Hayford K
The Pserenade Team
Microorganisms. 2021;9
Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for <5 years of age, 0.08 (0.06-0.09) for 5-17 years, 0.06 (0.05-0.08) for 18-49 years, 0.06 (0.05-0.07) for 50-64 years, and 0.05 (0.04-0.06) for >/=65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.
